Cardiff Oncology, Inc. 8-K

What Happened

• Cardiff Oncology, Inc. announced a business update and reported its financial results for the quarter ended March 31, 2026 via a press release dated May 14, 2026. The press release was furnished as Exhibit 99.1 to the company’s Form 8‑K filed the same day. The Form 8‑K was signed by Mani Mohindru, Interim Chief Executive Officer.

Key Details

• Filing date: May 14, 2026.
• Period covered: Quarter ended March 31, 2026 (Q1 2026).
• Disclosure type: Item 2.02 (Results of Operations and Financial Condition); press release furnished as Exhibit 99.1 under Item 9.01.
• Form 8‑K signed and furnished by Mani Mohindru as Interim CEO.

Why It Matters

• The company publicly released its quarterly results and a business update, which may include earnings, revenue, operating results, and operational progress relevant to investors. Investors should review the furnished press release (Exhibit 99.1) for the specific financial figures and any business highlights or guidance.
• The filing confirms the company’s official disclosure of Q1 2026 results and that the document was authorized and filed by the Interim CEO, ensuring the information is a formal, furnished disclosure under SEC rules.